Fundraising Fox
Ventyx Biosciences
San Diego, US · Founded 2019 · Delaware corporation · 229 employees on LinkedIn · 6 known investors
Find your way into Ventyx Biosciences
Sign up to see every warm intro you have to Ventyx Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ventyx Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
JC
Jigar ChokseyNamed on SEC filing
MA
CW
Christopher W. KruegerNamed on SEC filing
Board
SS
Somasundaram SubramaniamBoard director
RM
AR
RG
SG
WW
William WhiteBoard director
Investors · 6
New Science Ventureslisted by New Science VenturesGreenwich · $2M – $8M
How we know: funding news · prnewswire.com · the VCSheet dataset · Not right? Tell us
Third Point Ventureslisted by Third Point VenturesMenlo Park
How we know: Third Point Ventures's portfolio page · Not right? Tell us
venBio Partnerslisted by venBio PartnersSan Francisco
How we know: board seat on SEC Form D · funding news · prnewswire.com · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$192.3M disclosed across 3 rounds · 2021–2024
▶$27MraisedSep 2024 · 1 investors · OtherRule 506(b)
▶$27MraisedSep 2024 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Sheila GujrathiDirector
- Mark S. FormanExecutive Officer
- William WhiteDirector
- Allison HulmeDirector
- Matthew MooreExecutive Officer
- Onaiza Cadoret-ManierDirector
- Somasundaram SubramaniamDirector
- Raju MohanExecutive Officer, Director
- John NussExecutive Officer
- Offering amount
- $27M
- Amount sold
- $27M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$51MraisedSep 2021 · 17 investors · OtherRule 506(b)
▶$51MraisedSep 2021 · 17 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Christopher W. KruegerExecutive Officer
- William WhiteDirector
- Jigar ChokseyDirector
- Richard GasterDirector
- Raju MohanExecutive Officer, Director
- Sheila GujrathiDirector
- Somasundaram SubramaniamDirector
- Aaron RoystonDirector
- Martin AusterExecutive Officer
- Offering amount
- $51M
- Amount sold
- $51M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$114.3MraisedJul 2021 · 24 investors · OtherRule 506(b)
▶$114.3MraisedJul 2021 · 24 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Raju MohanExecutive Officer, Director
- Jigar ChokseyDirector
- Sheila GujrathiDirector
- Aaron RoystonDirector
- Somasundaram SubramaniamDirector
- Martin AusterExecutive Officer
- William WhiteDirector
- Christopher W. KruegerExecutive Officer
- Richard GasterDirector
- Offering amount
- $114.3M
- Amount sold
- $114.3M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Ventyx Biosciences went on to found or lead other companies.
Related companies · 9
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Guardant HealthGuardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease. The company serves oncologists, patients, and biopharmaceutical firms with FDA-approved tests for cancer screening, early-stage risk assessment, and treatment selection.
VendeluxVendelux runs an AI-based event intelligence platform that helps B2B teams pick events, book meetings and attribute pipeline.
Scholar RockScholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases. The company uses a selective protein targeting approach designed to inhibit disease mechanisms rather than manage their downstream effects.
AlumisAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
RelayRelay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques. The platform serves pharmaceutical and biotech researchers seeking to accelerate drug discovery across multiple phases of development.
ClementiaIpsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
TipRanksFinancial analysis and stock research platform.
Syndax PharmaceuticalsSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
Companies working in the same space as Ventyx Biosciences.
In the news
Frequently asked questions
- Who are Ventyx Biosciences's investors?
- Ventyx Biosciences's investors include New Science Ventures, Third Point Ventures, venBio Partners, Wellington Management, SilverArc Private, venBio Global Strategic.
- How much funding has Ventyx Biosciences raised?
- Ventyx Biosciences has disclosed $192.3M raised across 3 rounds.
- Where is Ventyx Biosciences headquartered?
- Ventyx Biosciences is headquartered in San Diego, US.